Introduction: Coronavirus disease 2019 (COVID-19) is a pandemic that has affected #x3e;188 countries, involved #x3e;24 million people, and caused #x3e;840,000 deaths. COVID-19, in its severe form, presents as acute respiratory distress syndrome (ARDS), shock, and multiorgan failure. Thrombotic microangiopathy of the lungs and kidneys has been observed in these patients. Elevated D-dimer levels have been observed in people with serious COVID-19 illness, and this could be helpful in guiding treatment with anticoagulation in these patients. Objective: To analyze the role of anticoagulation as a treatment modality for COVID-19. Methods: We present the unique case of a COVID-19 patient who developed sepsis, ARDS, acute kidney injury, and deep-vein thrombosis (DVT), who was deteriorating clinically. She was treated with anticoagulation. Results: There was rapid recovery after treatment with systemic anticoagulation. Conclusions: Systemic anticoagulation could prove to be essential in the treatment of CO­VID-19. Further studies are required to assess its role in improving long-term morbidity and mortality in these patients.
Cardiorenal Med

中文翻译：

---

COVID-19 相关的全身性血栓栓塞：病例报告和文献综述

简介： 2019 年冠状病毒病 (COVID-19) 是一种流行病，已影响 #x3e;188 个国家，涉及 #x3e;2400 万人，并造成 #x3e;840,000 人死亡。严重的 COVID-19 表现为急性呼吸窘迫综合征 (ARDS)、休克和多器官衰竭。在这些患者中观察到肺和肾的血栓性微血管病。在患有严重 COVID-19 疾病的患者中观察到 D-二聚体水平升高，这可能有助于指导这些患者的抗凝治疗。目的：分析抗凝治疗作为 COVID-19 治疗方式的作用。方法：我们介绍了一名患有败血症、ARDS、急性肾损伤和深静脉血栓 (DVT) 且临床病情恶化的 COVID-19 患者的独特病例。她接受了抗凝治疗。结果：全身抗凝治疗后恢复迅速。结论：全身抗凝治疗可能对治疗 COVID-19 至关重要。需要进一步的研究来评估其在改善这些患者的长期发病率和死亡率方面的作用。
心肾医学